← Back to Search

NAD+ precursor

Basis for Acute Kidney Injury

Phase 2

Waitlist Available

Led By Bernardo Mendes, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial will test if a supplement can prevent kidney injury in people undergoing surgery to repair an aortic aneurysm.

Eligible Conditions

Acute Kidney Injury

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

AKI

Secondary outcome measures

Bowel ischemia

Myocardial infarction

Nicotinamide Adenine Dinucleotide (NAD), Nicotinamide Mononucleotide (NMN), and Nicotinamide Riboside (NR)

+3 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: BasisActive Control1 Intervention

The investigational product, Basis™, contains a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels. Also contains Pterostilbene (Ptero) that is a stilbenoid compound, characterized by two aromatic rings connected by a methylene bridge backbone, and it has two methoxy groups and one hydroxyl group extending from the aromatic rings.

Group II: PlaceboPlacebo Group1 Intervention

Correspondent placebo, a capsule not containing the active component.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,206 Previous Clinical Trials

3,766,845 Total Patients Enrolled

11 Trials studying Acute Kidney Injury

5,799 Patients Enrolled for Acute Kidney Injury

Elysium HealthIndustry Sponsor

15 Previous Clinical Trials

36,539 Total Patients Enrolled

1 Trials studying Acute Kidney Injury

24 Patients Enrolled for Acute Kidney Injury

Bernardo Mendes, MDPrincipal InvestigatorMayo Clinic

1 Previous Clinical Trials

150 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers currently recruiting for this experiment?

"Clinicaltrials.gov has reported that this medical research initiative is actively seeking participants, with the first posting on December 1st 2020 and last update being February 9th 2022."

Answered by AI

What is the aggregate figure of participants in this clinical experiment?

"Affirmative. Online records from clinicaltrials.gov demonstrate that this trial, first introduced on December 1st 2020, is actively searching for participants to enroll. A total of 238 patients are needed across one location."

Answered by AI

Are there any prior investigations into Basis' efficacy?

"Currently, there are 15 Basis-related studies taking place with 1 trial in its final phase. Although the majority of these experiments occur at Iowa City, IA; 19 research sites around the nation host trials for this treatment modality."

Answered by AI

Has the Basis product been given regulatory approval by the FDA?

"Our team at Power assigned a score of 2 to Basis due to the fact that there is limited data available regarding its efficacy, but some evidence suggesting it could be safe."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

Bernardo C. Mendes 2020. "Protection From Acute Kidney Injury (AKI) With Basis™ Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04342975.